Cresco Labs (CRLBF) announced that it has been conditionally awarded a Texas Compassionate Use Program License. It is a vertically integrated license, allowing Cresco Labs to cultivate, process and dispense medical cannabis, the company stated. “Texas patients deserve access to consistent, quality medicine, and we’re excited to deliver it. Our track record in medical markets reflects our ability to build robust programs that put patients and communities first. Winning a license in Texas through a merit-based application points to Cresco Labs’s deep regulatory expertise and thoughtful approach to meaningful local engagement. Organic licensing enables capital-efficient market entry, and our cash generation and balance sheet give us the financial flexibility to invest and grow a scaled, long-term platform,” said Charlie Bachtell, CEO of Cresco Labs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRLBF:
- Cresco Labs OTC Balances Strong Margins With Near-Term Strain
- Cresco Labs price target lowered to C$2.25 from C$2.50 at Canaccord
- Cresco Labs Grows Cash Flow and Margins Despite 2025 Impairment Charges
- Is CRLBF a Buy, Before Earnings?
- Cresco Labs Sets March 5 Date to Report Q4 and Full-Year 2025 Results
